Stockscreener 앱 받기
10.36
1.80%
-0.19
시간 외 거래:
10.41
0.05
+0.48%
전일 마감가:
$10.55
열려 있는:
$11
하루 거래량:
1.63M
Relative Volume:
0.66
시가총액:
$1.85B
수익:
$15.36M
순이익/손실:
$-276.48M
주가수익비율:
-6.4232
EPS:
-1.6129
순현금흐름:
$-235.87M
1주 성능:
+4.75%
1개월 성능:
+16.01%
6개월 성능:
+159.65%
1년 성능:
+203.81%
1일 변동 폭
$10.30
$11.49
1주일 범위
$9.6101
$11.49
52주 변동 폭
$1.775
$11.49
릴레이 테라퓨틱스 Stock (RLAY) Company Profile
명칭
Relay Therapeutics Inc
전화
617-370-8837
주소
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
10.36 | 1.85B | 15.36M | -276.48M | -235.87M | -1.6129 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
릴레이 테라퓨틱스 Stock (RLAY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-26 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-12-12 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-04-17 | 개시 | Wells Fargo | Equal Weight |
| 2024-09-10 | 재개 | Goldman | Buy |
| 2024-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-09-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-05-10 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-04-20 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-04-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | 개시 | Raymond James | Outperform |
| 2023-02-03 | 개시 | Oppenheimer | Outperform |
| 2022-09-30 | 개시 | Barclays | Equal Weight |
| 2022-09-02 | 개시 | Stifel | Buy |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-02-01 | 개시 | Berenberg | Buy |
| 2021-07-21 | 개시 | BofA Securities | Buy |
| 2020-12-15 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-08 | 개시 | JMP Securities | Mkt Outperform |
| 2020-11-05 | 개시 | H.C. Wainwright | Buy |
| 2020-08-10 | 개시 | Cowen | Outperform |
| 2020-08-10 | 개시 | Goldman | Buy |
| 2020-08-10 | 개시 | Guggenheim | Buy |
| 2020-08-10 | 개시 | JP Morgan | Neutral |
모두보기
릴레이 테라퓨틱스 주식(RLAY)의 최신 뉴스
Commodore Capital LP Raises Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Should Relay’s Zovegalisib Momentum and New Legal Forum Rules Require Action From Relay Therapeutics (RLAY) Investors? - simplywall.st
Relay Therapeutics (NASDAQ:RLAY) Reaches New 1-Year High After Analyst Upgrade - MarketBeat
Guggenheim Issues Positive Forecast for Relay Therapeutics (NASDAQ:RLAY) Stock Price - MarketBeat
Guggenheim Raises Price Target for Relay Therapeutics (RLAY) to $22 | RLAY Stock News - GuruFocus
Can Relay Therapeutics Inc expand into new markets2026 Market Sentiment & Growth Focused Stock Reports - baoquankhu1.vn
Relay Therapeutics Files Amended and Restated Bylaws with SEC – Key Company Information and Filing Details - Minichart
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Insider Sell: Thomas Catinazzo Sells Shares of Relay Therapeutics Inc (RLAY) - GuruFocus
Relay Therapeutics Updates Bylaws on Federal Securities Litigation - TipRanks
Relay Therapeutics (NASDAQ:RLAY) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Zovegalisib Milestones To Shape The Future Of Relay Therapeutics - RTTNews
Investment Review: Can Relay Therapeutics Inc sustain its profitability2026 Summary & Risk Managed Trade Strategies - baoquankhu1.vn
A Look At Relay Therapeutics (RLAY) Valuation After Earnings Update And New Shelf Registration - Sahm
Relay Therapeutics Experiences Revision in Stock Evaluation Amid Market Fluctuations - Markets Mojo
Wells Fargo Initiates Coverage of Relay Therapeutics (RLAY) with Equal-Weight Recommendation - MSN
Should I add Relay Therapeutics Inc stock to my portfolio2025 Technical Patterns & Weekly High Conviction Ideas - baoquankhu1.vn
Relay Therapeutics: Breakthrough Designation Sets The Stage For A Key Zovegalisib Data Catalyst - Seeking Alpha
Relay Therapeutics Stock Price Rises 6% - National Today
Relay Therapeutics (NASDAQ:RLAY) Stock Price Up 6%Should You Buy? - MarketBeat
Why Relay Therapeutics (RLAY) Is Up 14.8% After 2025 Beat, FDA Breakthrough Win for Zovegalisib - Sahm
Relay Therapeutics, Inc. (NASDAQ:RLAY) Sees Large Decrease in Short Interest - MarketBeat
Citizens reiterates Relay Therapeutics stock rating ahead of data By Investing.com - Investing.com Canada
Aug Levels: Is Relay Therapeutics Inc stock showing strong momentum2025 Analyst Calls & Smart Investment Allocation Tips - baoquankhu1.vn
RLAYRelay Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Relay Therapeutics’ Promising Path with FDA Approvals and Revenue Growth - timothysykes.com
Bank Watch: What is the earnings history of Relay Therapeutics IncWeekly Profit Summary & Growth Focused Stock Pick Reports - baoquankhu1.vn
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March - Sahm
Relay Therapeutics Surges After Breakthrough Designation for Breast Cancer Treatment - StocksToTrade
Relay Therapeutics’ Q4 Financial Performance Surges Amid Breakthrough Recognition - timothysykes.com
Relay Therapeutics (RLAY) Valuation After Breakthrough Therapy Win And Narrower Loss Attracts Fresh Investor Interest - Yahoo Finance
Relay Therapeutics (RLAY) Losses Of US$276.5 Million Test Bullish Revenue Growth Narrative - simplywall.st
Relay Therapeutics stock hits 52-week high at 9.64 USD By Investing.com - Investing.com Australia
Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million - AOL.com
Relay Therapeutics, Inc. (RLAY) Stock Analysis: Exploring a 61.57% Potential Upside in Precision Medicine - DirectorsTalk Interviews
RLAY: Wells Fargo Raises Price Target to $15, Maintains Overweig - GuruFocus
Wells Fargo & Company Boosts Relay Therapeutics (NASDAQ:RLAY) Price Target to $15.00 - MarketBeat
RLAY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Relay Therapeutics Shares Jump 19% On Earnings And Pipeline Progress - Nasdaq
Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week High on Strong Earnings - MarketBeat
Relay Therapeutics stock hits 52-week high at 9.64 USD - Investing.com
A Look At Relay Therapeutics (RLAY) Valuation As Shares Rebound And Trade Below Analyst Targets - simplywall.st
Decoding Relay Therapeutics Inc (RLAY): A Strategic SWOT Insight - GuruFocus
Relay Therapeutics (NASDAQ:RLAY) Announces Quarterly Earnings Results - MarketBeat
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones - Investing News Network
Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Relay Therapeutics (RLAY) Surpasses Q4 Revenue Estimates, Eyes C - GuruFocus
Relay Therapeutics Q4 Loss Narrows, Revenue Rises; Cash Runway Into 2029 - marketscreener.com
Earnings Flash (RLAY) Relay Therapeutics Posts Q4 Loss Per Share $0.32, vs. FactSet Est of $0.40 Loss - marketscreener.com
Relay Therapeutics beats Q4 revenue expectations - TradingView
Relay Therapeutics Q4 Earnings Assessment - Benzinga
릴레이 테라퓨틱스 (RLAY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.48%
1.21%
자본화:
|
볼륨(24시간):